- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Immunovant Inc(IMVT)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for IMVT
11/13/2026: IMVT (2-star) is currently NOT-A-BUY. Pass it for now.
Immunovant is a clinical-stage biotechnology company focused on developing innovative FcRn inhibitors for autoimmune diseases. Its main strength lies in a promising pipeline targeting the well-validated FcRn pathway with an emphasis on patient-friendly subcutaneous delivery. The primary growth story revolves around the potential for its next-generation molecule, IMVT-1402, to differentiate itself in a competitive market. However, the company faces high risks, including the absence of commercial revenue, significant execution hurdles in clinical trials, and intense competition from established large-cap biotech firms. It is best suited for growth-oriented investors with a high risk tolerance who are monitoring clinical data readouts and regulatory progress.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit while signal remains positive | The company is a classic clinical-stage biotech bet on disruptive innovation in the autoimmune space. |
| Momentum investor | Mixed fit | Momentum is highly dependent on clinical trial results and regulatory news cycles. |
| Value investor | Weak fit | There are no earnings or revenue to support traditional value-based valuation metrics. |
| Dividend investor | Weak fit | The company is in an early growth phase and does not pay dividends. |
| Low-risk investor | Weak fit | The inherent risk of binary clinical trial outcomes makes this unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotech stocks often experience extreme swings based on clinical trial data releases. |
| Valuation risk | High | Valuation is based on speculative future cash flows from drugs not yet on the market. |
| Competition risk (FcRn market leaders) | High | Established players have significant advantages in trial execution and commercial infrastructure. |
| Business quality | Medium | The company benefits from Roivant's platform, but the lack of commercialized revenue limits quality assessments. |
| Dividend income | Low / none | No dividend payments exist or are expected in the near future. |
| Execution risk | High | The success of the company rests entirely on the successful clinical development and regulatory approval of its pipeline. |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 7.07B USD | Price to earnings Ratio - | 1Y Target Price 48.5 |
Price to earnings Ratio - | 1Y Target Price 48.5 | ||
Volume (30-day avg) 1.5M shares | Beta 0.94 | 52 Weeks Range 21.86 - 45.42 | Updated Date 11/15/2026 |
52 Weeks Range 21.86 - 45.42 | Updated Date 11/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.56 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 45.5%
- Active BUY / eligible
- 20 / 44
- 30-Day BUY Count Change
- +13
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Rolling Over
The price momentum is slowing down and beginning to turn downward.

Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 26.6% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Clinical Development | Developing FcRn inhibitors to treat autoimmune diseases. | The company currently makes no money; investors are funding development for potential future revenue. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 6.17B | Price to Sales(TTM) - |
Enterprise Value 6.17B | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -14.12 | Shares Outstanding 206.95M | Shares Floating 92.16M |
Shares Outstanding 206.95M | Shares Floating 92.16M | ||
Percent Insiders 56.2 | Percent Institutions 55.44 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

